title: [Intravitreal implantation of Ozurdex® chronic delivery system for management of macular edema related to retinitis pigmentosa: case report].
abstract: Retinitis pigmentosa denotes a heterogeneous group of rare genetic diseases in which both rods and cones eye are damaged. It is a disease of poor prognosis. We describe the case of a 22 years old woman successfully treated with intravitreal implant of dexamentasone (OZURDEX®, Allergan, USA) for the treatment of macular edema due to retinitis pigmentosa.
authors: Guilherme
authors: G
authors: Buchaim
authors: Marcussi Palata
authors: MP
authors: Rezende
authors: Maurício
authors: M
authors: Maia
mesh_terms: D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections / Q000379:methods*; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D012174:Retinitis Pigmentosa / Q000150:complications / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone